References
- Current medical diagnosis and treatment Allergic and immunologic disorders Adelman, D. C.;Terr, A.;L. M. Tierney;S.J.McPhee;M. A. Apadakis (Eds.)
-
Nature (Lond.)
v.236
Definition and antagonism of histamine
$H_2$ -receptors Black, J.W.;Dunca, W.A.M.;Durant, C.J.;Ganellin, C.R.;Parsons, E.M. - Am. Fam. Physician v.52 no.2 Antihistamines : The old and the new Peggs, J. F.;Shimp, L. A.;Opdycke, R. A.
- Drug Evaluations Annual Histamine and antihistamines Ambre, J. J.;Bennet, D. R.;Cranston, J. W.;Dickinson,B. D.;Mark,E. R.;Glade,M. J.;Kosman, M. E.;Lampe, K.F.;McCann, M. A.;Pang, S. J.;Weaver, R. H.
- Drugs v.12 Antimotion siknee and antiemetic drugs Wood, C. D
- Drugs v.17 Antimotion sickness and antiemetic drugs Wood, C. D.
- Drugs v.30 Newer non-sedating antihistamines, will replace order agent? Brandon, M. L.
- J. Am. Acad. Dermatol. v.24 Treatment of urticaria and angioedema : Low-sedating H1-type antihistamines Soter, N. A.
-
J. Allergy clin. immunol.
v.86
$H_1$ -receptor antagonist treatment of seasonal allergic rhinitis Kaiser, H. B. - Dermatol. Clin v.9 Antihistamine update Herman, L. E.;Bernhard, J. D.
-
Allergy and clinical immunology
v.86
Recent advances in
$H_1$ -receptor antagonist treatment Simons, F. E. R. - J. Am. Acad. Dermatol v.19 Review of nonsedating H1 antihistamines in treatment Monroe, E. W.
-
J. Pharmacol. Exp. Ther.
v.242
Selectivity of muscarinic antagonist in radioligand and in vivo experiment for the putative
$M_1,M_2 and M_3$ receptors Doods, H. N.;Mathy, M. J.;Davidesko, D.;van charldorp, K. J.;de Jonge, A.;van zwieten, P. A. - Br. J. Pharmacol. v.86 Action of agonist and antagonists at muscarinic receptors present on ileum and atria in vitro Clague, R. V.;Eglen, R. M.;Strachan, A. C.;Whiting, R. L.
- Br. J. Pharmacol. v.90 Competitive and noncompetitive antagonism exhibited by 'selective' antagonist at atrial and ileal muscarinic receptor subtypes Eglen, R. M.;Whiting, R. L.
- Facts Book The G-protein linked receptor Watson, S.;Arkistall, S
- Life sci v.56 no.s11/12 The design of novel methoctramine-related tetraamines as muscarinic receptor subtype selective antagonists Mechioore, C.;Minarini, A.;Budriesi, R.;Chiarini A.;Spampinato S.;Tumiatti V.
-
Life sci
v.60
no.13-14
The
$M_5$ (m5) receptor subtype : fact or fiction? Reever C. M.;Ferrari-DiLeo G.;Flymn D. D. - Yakhak Haeji v.32 Action on the cardiac muscarinic receptor Lee, S. W.;Park, Y. J.;Lee, J. S.;Ha, K. W.;Jin, K. D.
- Yakhak Hoeji v.37 Relative potency of antihistaminics for H1- and muscarinic receptor Lee, S. W.;Park, Y. H.;Lee, J. S.
-
J. Pharmacol. Methods
v.7
A simple method for the purification of rat brain
$Na^+,K^+-adenosine triphosphatase(ATPase) Mayrand, R. R.;Fullerton, D. S.;Ahemd, K. - J. Biol. Chem. v.193 Protein measurement with the folin-phenol reagent Lowy, O. H.;Rosebrough, N. J.;Farr, A. L.;Randall, R. J.
- J. Biol. Chem. v.249 Nature of the transport ATPase-digitalis complex. X. Thermodynamics of the rate of ouabain binding Wallick, E. T.;Schwartz, A
- Acad. Sci v.5 The attraction of proteins for small molecules and ions Ann N. Y. Scatchard, G
-
Biochem. Pharmacol.
v.22
Relationship between the inhibition constant (ki) and the concentration of inhibition of which cause 50 percent inhibition
$(I_50)$ of an enzymatic reaction Cheng, Y.C.;Prusoff, W.H. - J. Clin pharmacol. v.27 Pharmacokinetics and dose proportion-ality of loratadine Hilber, J.
- Present at allergy council of america symposium How antihitamines act on the central nervous system Gengo, F. M.
- Proc. Nat. Acad. Sci. U.S.A. v.71 no.5 Muscarinic cholinergic binding rat brain Yamamura, H. I.;Snyder, S. H.
- J. Pharmacol. Exp. Ther. v.228 no.3 Comparison of [^3H] pirenzepine and [^3H]quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rat brain Luthin, G. R.;Wolfe, B. B.
-
Arznein-Forsch/Drug Res
v.36
Animal pharmacology of the selective histamine
$H_1$ -receptor antagonist tazifylline Poizot, A.;Dumez, D.;Ferrandon, P.;Lefournier, C;Michel, A;Armstrong, J. M. -
Mol. Pharmacol.
v.21
In vitro and in vivo binding charateristics of a new long-acting histamine
$H_1$ -receptor antagonist tazifyline Poizot, A.;Dumez, D.;Ferrandon, P.;Lefournier, C.;Michel, A.;Armstrong, J. M. -
Mol. Pharmacol.
v.26
$[^3H]$ Pirenzepine and$[^3H]$ QNB binding to brain muscarinic receptors. Differences in measured receptor density are not explained by difference in receptor isomerization Luthin, G. R.;Wolfe, B. B. - Mol.Pharamacol. v.27 Bisquaternary pyridium oximes as allosteric inhibitors of rat brain muscarinic receptors Kloog, Y.;Sokolovsky, M.
- J. Pharmacol. Exp. Ther. v.236 Stabilization of antagonist binding to cardiac muscarinic acetlcholine receptor by gallamine and other neuromuscular blocking drug Nedoma, J.;Tucek, S.;Danilov, A. F.;Shelkovnikov, S. A.
- Biochem. Biophys. Commum v.121 Effects of verapamil on the binding properties of rat heart muscarinic receptors.:Evidence for an allosterteric site Waelbroeck M.;DeNeef, P.;Roberecht, P.;Christophe J.
-
Yakhak Hoeji
v.34
no.4
Interatction of antihistaminics with muscarinic receptor(II) : Action on the cerebral muscarinic
$M_!$ receptor Lee, S. H.;Park, Y. J.;Park, I. S.;Lee, J. S.